CN1264509C - Precursor liposome preparation containing silybum marianum extract and its preparing process - Google Patents
Precursor liposome preparation containing silybum marianum extract and its preparing process Download PDFInfo
- Publication number
- CN1264509C CN1264509C CN 200410014407 CN200410014407A CN1264509C CN 1264509 C CN1264509 C CN 1264509C CN 200410014407 CN200410014407 CN 200410014407 CN 200410014407 A CN200410014407 A CN 200410014407A CN 1264509 C CN1264509 C CN 1264509C
- Authority
- CN
- China
- Prior art keywords
- liposome
- pro
- flavanolignan
- compounds
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention relates to a compound in a flavone lignan class such as a precursor liposome of silymarin or a silymarin phospholipid composition and a preparing method of industrialized application. The compound in a flavone lignan class is mainly composed of compounds in a flavone lignan class, a water-solubility carrier or a non water solution, and surface active agents. The compound in a flavone lignan can contain film forming material. The obtained precursor liposome can be made into tablets or hard capsules or soft capsules or oral medicinal liquid or injections according to a conventional method; the storage stability is obviously improved; the biological availability is 5 to 10 times of that of a conventional tablet.
Description
Technical field
The present invention relates to flavanolignan's compounds proliposome preparation and preparation method thereof, be specially proliposome preparation of the flavanolignan's compounds that extracts in the medicinal plants Herba Silybi mariani and preparation method thereof.
Background technology
Silymarin is natural flavanolignan's compounds; for the fruit of feverfew Herba Silybi mariani is made with extra care the mixture that obtains through extracting; have direct removing active oxygen, suppress 5 '-lipoxygenase, protect liver plasma membrane, promote to be damaged hepatocyte synthetic DNA and pharmacological actions such as structural protein, immunomodulating and anti-hepatic fibrosis; this poison of drug is little; no teratogenesis and mutagenesis; in blood fat reducing, prevent and treat aspects such as atherosclerosis, prevention of brain ischemia, antiplatelet aggregation and demonstrate gratifying effect, be a kind of liver disease medicine with applications well prospect.Main component is flavanolignan's compounds and little fat oil, fatty acid etc. in the silymarin.Flavanolignan's compounds is its effective ingredient, comprises silibinin, Silychristin, silidianin etc., and this compounds both had been insoluble in water, and was fat-soluble also very poor.
The silymarin tablet of clinical practice at present mostly is to adopt solid dispersion technology to be made into Polyethylene Glycol eutectic, polyvinylpyrrolidone coprecipitate, Benexate Hydrochloride, but the defective of these methods is that the raising of the dissolution of silymarin is still limited.Also have a lot of bibliographical informations at present, silymarin and phospholipids incorporate are formed complex, complex improves the fat-soluble of silymarin to a certain extent and it is prepared into capsule, for example homemade silymarin capsule (trade name: the water woods is good), but its dissolution is still not ideal enough.Chinese patent application silymarin oral microemulsion compositions (CN1316898A), it has used a large amount of oil phases, and the principle that forms according to microemulsion must add the surfactant of higher dosage in the prescription simultaneously, thereby improves dissolution or bioavailability.But for the patient who suffers from hepatopathy, take the burden that a large amount of oil can increase the weight of liver for a long time, and the surfactant of taking higher dosage for a long time also can there be infringement to health.
Summary of the invention
The technical problem to be solved in the present invention is to study the dissolution of the oral flavanolignan of a kind of effective raising compounds, do not contain vegetable oil or mineral oil, it is less relatively to contain dosage of surfactant, reaches the flavanolignan's compounds pro-liposome and the preparation thereof of good clinical effectiveness.But the present invention also comprises the preparation method of the industrializing implementation of research described flavanolignan compounds pro-liposome and preparation thereof.
For addressing the above problem, the invention provides following technical scheme.
A kind of pro-liposome, mainly by phosphatide complexes, water-solubility carrier or the non-aqueous solution of flavanolignan's compounds or flavanolignan's compounds, surfactant by weight 1: 0-30.0: 0.1-15 part is formed; Flavanolignan's compounds, water-solubility carrier or non-aqueous solution, surfactant proportioning preferably are by weight 1: 0.3-25.0: 0.5-10 part; Described pro-liposome can also add the filmogen of counting 0.1-30.0 part by weight; Proportioning is to add the filmogen of counting 0.2-15.0 part by weight preferably.
Pro-liposome of the present invention, its flavanolignan's compounds mainly comes from the extract in the natural drug Herba Silybi mariani, as the mixture that is selected from silibinin, Isosilybin, Silychristin, silidianin or chooses wantonly in them, that is: both can be can be pure compound such as silibinin, Isosilybin, Silychristin, silidianin, also can generally this mixture be simply referred to as silymarin by the mixture of forming optional in silibinin, Isosilybin, Silychristin and the silidianin.Though it is the natural drug Herba Silybi mariani that has drawn from that the present invention prepares flavanolignan's compounds of proliposome; but this does not get rid of the compounds with complete synthesis or semisynthetic flavanolignan, as silibinin, Isosilybin, Silychristin, silidianin or in them optional mixture prepare pro-liposome in the protection domain of the present invention.
Pro-liposome of the present invention, wherein water-solubility carrier is selected from sorbitol, mannitol, glucose, lactose, sodium chloride, sucrose, starch, dextrin, maltodextrin, cyclodextrin, microcrystalline Cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, sodium lauryl sulphate, Macrogol 4000, polyethylene glycol 6000, Stepanol MG, adipic acid or optional mixture in them.Pro-liposome of the present invention, the mixture that wherein non-water-soluble matchmaker is selected from ethanol, propylene glycol, glycerol, ethylene glycol monomethyl ether, Macrogol 200, Liquid Macrogol, PEG400, Macrogol 600,1,3 butylene glycol, tertriary amylo alcohol, benzyl alcohol, triacetyl glycerine, ethyl oleate, benzyl benzoate or chooses wantonly in them.Pro-liposome of the present invention, wherein surfactant is selected from the acidifying natural or hydrogenated vegetable oil of polyoxyethylene glycol, polyoxyethylene-anhydro sorbitol-fatty acid ester, polyoxyethylene fatty acid ester, ethylene oxide-propylene oxide copolymer, ethylene oxide-oxypropylene block copolymer, dioctyl sodium sulphosuccinate or sodium lauryl sulfate, phospholipid, propylene glycol list or di fatty acid ester, the esterification products of crude vegetal triglyceride and poly alkylene glycol, glyceryl monoacetate, diglyceride or glycerol list/two acid esters, fatty acid esters of sorbitan, sterol or derivatives thereof, the perhaps mixture of choosing wantonly in them.Pro-liposome of the present invention, wherein filmogen is selected from phospholipid, cholesterol, 18 ammonia, stearylamine, phosphatidic acid, Phosphatidylserine, perhaps the mixture of choosing wantonly in them.
Pro-liposome of the present invention, in its adjuvant, lactose is selected from spray-dried lactose, pelletiod lactose or Lactis Anhydrous; Starch is amylum pregelatinisatum; Cyclodextrin is a beta cyclodextrin; Polyoxyethylene-anhydro sorbitol-fatty acid ester condensation substance is polysorbas20, Tween 80; The acidifying natural or hydrogenated vegetable oil of polyoxyethylene glycol is polyoxyethylene hydrogenated Oleum Ricini, polyoxyethylene castor oil.Phospholipid both can be used as surfactant among the present invention, also can be used as filmogen.Phospholipid is selected from soybean phospholipid, lecithin or synthetic phospholipid, and phosphatidylcholine content is 60-97% in the used phospholipid of the present invention.Phosphatidylcholine content is at 70-89% in the phospholipid, and preparation is more stable.
The preparation method of aforementioned pro-liposome of the present invention comprises the steps:
With flavanolignan's compounds or flavanolignan's phospholipid complex, surfactant and lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them optional mixed liquor and/or phosphate buffer mixes, except that desolvating;
Perhaps with flavanolignan's compounds or flavanolignan's phospholipid complex, surfactant and water-solubility carrier or non-aqueous solution, with lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them optional mixed liquor and/or phosphate buffer mixes, except that desolvating;
Perhaps with flavanolignan's compounds or flavanolignan's phospholipid complex, surfactant, water-solubility carrier or non-water-soluble and filmogen, with lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them optional mixed liquor and/or phosphate buffer mixes, except that desolvating.
The preparation method of pro-liposome of the present invention specifically comprises the steps:
Flavanolignan's compounds or flavanolignan's phospholipid complex and surfactant be dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, form lipoids solution; Perhaps such lipid soln is joined in the water-solubility carrier, remove and desolvate; Perhaps such lipid soln is removed the back of desolvating and mix lyophilizing with water; Get the pro-liposome of flavanolignan's compounds or flavanolignan's phospholipid complex;
Perhaps, water-solubility carrier, filmogen and/or surfactant be dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, the phosphatide complexes that adds flavanolignan's compounds or flavanolignan's compounds, mix, remove and desolvate, get the pro-liposome of flavanolignan's compounds or flavanolignan's phospholipid complex;
Perhaps, surfactant is dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, after adding flavanolignan's compounds or flavanolignan's phospholipid complex, mix with water-solubility carrier again, remove and desolvate, get the pro-liposome of flavanolignan's compounds or flavanolignan's phospholipid complex;
Perhaps, flavanolignan's compounds or flavanolignan's phospholipid complex and surfactant be dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, remove the formation lipid film that desolvates; This film with ether and/or chloroform dissolving, is added phosphate buffer, after the emulsifying, remove organic solvent, again with after the phosphate buffer that is dissolved with water-solubility carrier and/or filmogen mixes, lyophilizing; Perhaps with this lipid film directly with after the phosphate buffer that is dissolved with water-solubility carrier and/or filmogen mixes, lyophilizing; Perhaps with this lipid film directly with after the water liquid that is dissolved with water-solubility carrier and/or filmogen mixes, lyophilizing; Get the pro-liposome of flavanolignan's compounds or flavanolignan's phospholipid complex;
Perhaps, non-aqueous solution is mixed with surfactant, add flavanolignan's compounds or flavanolignan's phospholipid complex mixing, get the pro-liposome of flavanolignan's compounds or flavanolignan's phospholipid complex.
In the preparation method of described pro-liposome, decompression or rotary evaporation in vacuo drying also can adopt spray drying method when the method for removing solvent can be used ice bath, room temperature or higher temperature, fluidized bed process, and polishing volatilizes solvent.The lower alcohol that relates in the preparation method is selected from methanol and/or ethanol, and rudimentary ether is selected from ether; When lower alcohol and rudimentary ether both or respectively be used alone, but also also mix together; Count 1-15 when wherein lower alcohol and rudimentary ether mix to use by weight: 1 part, its preferably proportioning count 2-12 by weight: 1 part; Phosphate buffer is PH4.0-7.8, and more suitable phosphate buffer is PH6.8-7.5; The pro-liposome of gained flavanolignan compounds or flavanolignan's phospholipid complex mixes with water, for example can mix with the water of PH1-12, forms liposome turbid liquor, and wherein the particle diameter of liposome is 100nm～1.0 μ m; The pro-liposome of gained flavanolignan compounds or flavanolignan's phospholipid complex can mix with conventional carrier pharmaceutically, makes capsule, soft capsule, tablet, granule, powder, perhaps injection by known technology on the pharmaceutics.
The flavanolignan's compounds of the present invention's preparation or the pro-liposome of flavanolignan's phospholipid complex, add water before taking and to form liposome turbid liquor, it can form liposome turbid liquor in various pH (pH1-12) aqueous solution, for example in the hydrochloric acid solution of 0.1mol/L, the particle diameter of its liposome is 100nm-1.0 μ m.This shows that flavanolignan of the present invention compounds or flavanolignan's phospholipid complex pro-liposome are not subjected to the influence of gastrointestinal tract PH in forming the liposome turbid liquor process.
The flavanolignan's compounds raw material that adopts when pro-liposome of the present invention prepares is mainly from Herba Silybi mariani extract or its phosphatide complexes.Herba Silybi mariani extract can be silibinin, Isosilybin, Silychristin, silidianin or optional mixture in them, and their optional mixture abbreviate silymarin in the present invention as.With silibinin, Isosilybin, Silychristin, silidianin or silymarin, perhaps their phosphatide complexes is prepared into pro-liposome, the dispersibility and the hydrophilic of medicine have been improved, dissolution significantly improves, in addition, be wrapped in and make the easier permeate through cell membranes of medicine enter blood circulation or enter histiocyte inside in the phospholipid bilayer, thus obtain higher blood drug level and the body that slows down in elimination speed, bioavailability is significantly improved.Phospholipid as silymarin pro-liposome carrier also has stable liver plasma membrane effect, with silymarin performance cooperative effect.
Pro-liposome of the present invention can be mixed with various pharmaceutical preparatioies according to common process and method, for example powder agent, granule, tablet, capsule and solution.For example lubricant and other drug additive can be added in the pro-liposome, this pro-liposome is processed into powder or graininess, then this powder or granule are filled in the hard capsule case, prepare hard capsule thus; Suitable additive is added in the pharmaceutical composition, with this mixture tabletting, can prepares tablet thus then; Can prepare oral liquid or injection in the water by pharmaceutical composition is dissolved in.Flavanolignan's compounds proliposome made from the inventive method can significantly improve the bin stability of medicine, can make this pro-liposome form the liposome turbid liquor that particle diameter is 100nm～1.0 μ m again in gastric juice, bioavailability is 5-10 a times of conventional tablet.
Description of drawings
Fig. 1: the dissolution of the embodiment of the invention 5 silymarin pro-liposome and silybin (Zhenjiang the 3rd pharmaceutical factory), Legalon (Madaus AG) and water woods good (day Shi Li Pharmacy stock Co., Ltd) relatively.
Fig. 2: the dissolution of the embodiment of the invention 12 silymarin pro-liposome and silybin (Zhenjiang the 3rd pharmaceutical factory), Legalon (Madaus AG) and water woods good (day Shi Li Pharmacy stock Co., Ltd) relatively.
The specific embodiment
Raw material sources: commercially available silymarin (Panjin Green grace living resources development corporation, Ltd. contains silibinin 20%～98%, and all the other are flavanolignan's compounds such as silidianin, Silychristin and little fat oil, fatty acid etc. and a small amount of relevant composition).Also can from Herba Silybi mariani or other plant, extract according to a conventional method.
Self-control silymarin phosphatide complexes, preparation method referring to: European patent 0209038, the mass ratio 1 of silymarin and phospholipid in the self-control silymarin phosphatide complexes: 0.1-2, the mass ratio of silymarin and phospholipid can be 0.8: 0.2-1.
Following example is used to further specify the present invention, but is not the restriction to its scope.
Embodiment 1
Get 1.0g silymarin phosphatide complexes, 5.0g being dissolved in 50 milliliters of the methanol, soybean phospholipid (phosphatidylcholine content is 70%) and 1.0g Tween 80 (25 ℃) under room temperature make lipoids solution, take by weighing the 3.0g sorbitol, lipoids solution is added in the sorbitol under the vacuum rotary evaporation gradually fling to methanol, promptly get the silymarin pro-liposome.
Embodiment 2:
Take by weighing the 1.0g silymarin, 8.5g being dissolved in 30 milliliters of the methanol in 20 ℃, lecithin (phosphatidylcholine content is 80%) makes lipoids solution, take by weighing the 3.0g beta-schardinger dextrin-, lipoids solution is added in the beta-schardinger dextrin-under the vacuum rotary evaporation gradually fling to methanol, promptly get the silymarin pro-liposome.
Embodiment 3:
Take by weighing the 1.0g silymarin, 1.5g being dissolved in 10 ml methanol and 40 milliliters of oxolane mixed solutions in 20 ℃, lecithin (phosphatidylcholine content is 90%) makes lipoids solution, fling to organic solvent in 37 ℃ and form exsiccant liposome, the room temperature vacuum is placed 24h then, take by weighing the exsiccant liposome of 1.0g, it is ultrasonic to being completed into liposome turbid liquor to add 5 ml distilled waters, and lyophilizing then promptly gets the silymarin pro-liposome.
Embodiment 4:
Get 1.0g silymarin and 15.0g synthetic phospholipid (Shanghai Taiwei Pharmaceutical Co., Ltd., phosphatidylcholine content is 92%) in 20 ℃ of mixed solutions that are dissolved in 5 milliliters of ether and 60 ml methanol, ice bath is flung to organic solvent and is become lipid film under vacuum state then, with 2 milliliters of ether with membrane elution after, the phosphate buffer that adds 2 milliliters of pH7.4, excusing from death makes it be emulsified into W/O Emulsion, this Emulsion rotary evaporation under vacuum is flung to organic solvent form Colloidal fluid, and then adding is dissolved with the 2.0g sodium carboxymethyl cellulose, 0.2g the phosphate buffer of 3 milliliters of pH6.8 of 18 ammonia makes its hydration, lyophilizing then promptly gets the silymarin pro-liposome.
Embodiment 5:
Take by weighing 8.5g soybean phospholipid (phosphatidylcholine content is 79%), 0.2g cholesterol and 1.5g mannitol under room temperature (25 ℃) are dissolved in the ethanol, add the 1g silymarin then, stirring is dissolved fully until silymarin, gained solution rotary evaporation under vacuum is flung to ethanol, promptly get the silymarin pro-liposome, being dissolved in water before this precursor liposome is used promptly becomes liposome oral fluid.
Embodiment 6:
Getting 6.5g soybean phospholipid (phosphatidylcholine content is 83%) is dissolved in the mixed solution of 10 milliliters of ether and 30 ml methanol with 1.5g polyoxyethylene hydrogenated Oleum Ricini (25 ℃) under room temperature, add the 1g silymarin then, stirring is dissolved fully until silymarin, get 5g glucose powder, be added drop-wise to ether and methanol mixed solution in the glucose powder slowly and constantly grind and remove ether and methanol, promptly get the silymarin pro-liposome, this precursor liposome fill in hard capsule, is capsule.
Embodiment 7:
Take by weighing 1.0g silymarin, 3.0g soybean phospholipid (phosphatidylcholine content is 80%) and be dissolved in the mixed solution of 5 milliliters of ether and 60 ml methanol with 0.5g polyoxyethylene hydrogenated Oleum Ricini (25 ℃) under room temperature, ice bath is flung to organic solvent and is become lipid film under vacuum state then; Sorbitol 1.5 grams are dissolved in the phosphate buffer of pH7.4, this buffer is added hydration in the above-mentioned lipid film, lyophilizing then, promptly get the silymarin pro-liposome, with the fine little element of this precursor liposome and crystallite, polyvinylpyrrolidone, magnesium stearate mix homogeneously, direct compression is tablet.
Embodiment 8:
Take by weighing 1.0g silymarin, 3.5g lecithin (phosphatidylcholine content is 70%) and be dissolved in the mixed solution of 5 milliliters of ether and 60 ml methanol with 0.5g polyoxyethylene hydrogenated Oleum Ricini (25 ℃) under room temperature, ice bath is flung to organic solvent and is become lipid film under vacuum state then; (poloxamer both can be used as water-solubility carrier at this with 5.0g sorbitol, 2.0g poloxamer, also play the effect of thickening agent and suspending agent behind the formation liposome turbid liquor) be dissolved in 3 ml distilled waters, this distilled water is added hydration in the above-mentioned lipid film, lyophilizing then, promptly get the silymarin pro-liposome, this precursor liposome is mixed with pregelatinized Starch, ethanol liquid with polyvinylpyrrolidone is that binding agent is granulated, dry back granulate, with an amount of polyethylene glycol 6000 mix homogeneously, tabletting is tablet again.
Embodiment 9:
Take by weighing 5.5g PEG400 and 1.0g polysorbas20 (25 ℃) mixing under room temperature, add the 1g silymarin then, stir and dissolve fully, gained solution quantitatively is filled in the soft capsule, promptly make the silymarin soft capsule until silymarin.
Embodiment 10:
Take by weighing the propylene glycol of 4.5g and polyoxyethylene hydrogenated Oleum Ricini (25 ℃) mixing under room temperature of 0.5g, add the 1g silymarin then, stir and dissolve fully, gained solution quantitatively is filled in the soft capsule, promptly make soft capsule until silymarin.
Embodiment 11:
The polyoxyethylene castor oil that takes by weighing 6.0g ethylene glycol monomethyl ether and 0.8g is in 37 ℃ of mixings, add 1g silymarin phosphatide complexes then, stirring is dissolved fully until the silymarin phosphatide complexes, and gained solution quantitatively is filled in the soft capsule, promptly makes soft capsule.
Embodiment 12:
Take by weighing 1.5g ethylene glycol monomethyl ether and 2.0g lecithin (phosphatidylcholine content is 79%) (25 ℃) mixing under room temperature, add the 1g silymarin then, stirring is dissolved fully until silymarin, and gained solution quantitatively is filled in the soft capsule, promptly makes the silymarin soft capsule.
Embodiment 13: external dissolution test
(embodiment 5 with aforementioned preparation of the present invention, silybin Zhenjiang the 3rd pharmaceutical factory), (trade name: the good day Shi Li of water woods Pharmacy stock Co., Ltd), the home-made Herba Silybi mariani tablet of moral (trade name: Legalon Madaus AG)) carries out dissolution relatively (referring to accompanying drawing) to silibinin phosphatide complexes hard capsule 12) with homemade commercially available Herba Silybi mariani oral solid formulation Herba Silybi mariani tablet (trade name:.
Experimental technique: with reference to dissolution experimental technique in the Chinese Pharmacopoeia 2000 editions.
Experimental condition: 900ml0.1MHCL, 37 ℃, 50 rev/mins
Liquid-phase condition: post: VP-ODS
Mobile phase: methanol: water: 0.02M potassium dihydrogen phosphate=65: 35: 3 (phosphoric acid is transferred pH4.0)
Detector: UV288nm
Flow velocity: 1ml/min
Sample size: 20 μ l
Preparation 45min of the present invention stripping 78.02%, and homemade commercially available silybin, the home-made Legalon tablet of moral (Legaron tablet) 45min still do not have stripping, the good hard capsule of water woods (silibinin phosphatide complexes) 45min stripping 12.78%, experimental data shows that the dissolution of preparation of the present invention significantly improves than prior art.
The dissolution that surplus experimental data shows all preparations in the embodiment of the invention all improves than prior art or significantly improves.
Claims (8)
1, a kind of pro-liposome is characterized in that: mainly by flavanolignan's compounds, water-solubility carrier or the non-aqueous solution, surfactant and the filmogen that are selected from silibinin, Isosilybin, Silychristin, silidianin or their mixture by weight 1: 0.3-25.0: 0.5-10: 0.1-30.0 part is formed.
2, the pro-liposome of claim 2 is characterized in that: its filmogen is counted 0.2-15.0 part by weight.
3, the pro-liposome of claim 1 is characterized in that: the mixture that water-solubility carrier is selected from sorbitol, mannitol, glucose, lactose, sodium chloride, sucrose, starch, dextrin, cyclodextrin, microcrystalline Cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, sodium lauryl sulphate, Macrogol 4000, polyethylene glycol 6000, Stepanol MG, adipic acid or chooses wantonly in them;
The mixture that non-aqueous solution is selected from ethanol, propylene glycol, glycerol, ethylene glycol monomethyl ether, Macrogol 200, Liquid Macrogol, PEG400, Macrogol 600,1,3 butylene glycol, tertriary amylo alcohol, benzyl alcohol, triacetyl glycerine, ethyl oleate, benzyl benzoate or chooses wantonly in them;
Surfactant is selected from esterification products, glyceryl monoacetate, diglyceride or glycerol list/two acid esters, fatty acid esters of sorbitan, the sterol of acidifying natural or hydrogenated vegetable oil, polyoxyethylene-anhydro sorbitol-fatty acid ester, polyoxyethylene fatty acid ester, ethylene oxide-propylene oxide copolymer, ethylene oxide-oxypropylene block copolymer, dioctyl sodium sulphosuccinate or sodium lauryl sulfate, phospholipid, propylene glycol list or di fatty acid ester, crude vegetal triglyceride and poly alkylene glycol of polyoxyethylene glycol, perhaps optional mixture in them;
Filmogen is selected from phospholipid, Phosphatidylserine, perhaps their mixture.
4, the pro-liposome of claim 3 is characterized in that: lactose is selected from spray-dried lactose, pelletiod lactose or Lactis Anhydrous; Starch is amylum pregelatinisatum; Cyclodextrin is a beta cyclodextrin; Polyoxyethylene-anhydro sorbitol-fatty acid ester is polysorbas20, Tween 80; The acidifying natural or hydrogenated vegetable oil of polyoxyethylene glycol is polyoxyethylene hydrogenated Oleum Ricini, polyoxyethylene castor oil; Phospholipid is selected from soybean phospholipid, lecithin or synthetic phospholipid, and phosphatidylcholine content is 60-97% in the phospholipid.
5, the preparation method of one of claim 1-4 pro-liposome comprises the steps:
With flavanolignan's compounds, surfactant, water-solubility carrier or non-aqueous solution and filmogen, with lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them optional mixed liquor and/or phosphate buffer mixes, except that desolvating.
6, the preparation method of claim 5 pro-liposome comprises the steps:
Water-solubility carrier, filmogen and surfactant be dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, add flavanolignan's compounds, mix, remove and desolvate, get the pro-liposome of flavanolignan's compounds;
Perhaps, flavanolignan's compounds and surfactant be dissolved in lower alcohol, rudimentary ether, ethyl acetate, oxolane, acetone, chloroform or in them in the optional mixed liquor, remove the formation lipid film that desolvates; This film with ether and/or chloroform dissolving, is added phosphate buffer, after the emulsifying, remove organic solvent, again with after the phosphate buffer that is dissolved with water-solubility carrier and filmogen mixes, lyophilizing; Perhaps with this lipid film directly with after the phosphate buffer that is dissolved with water-solubility carrier and filmogen mixes, lyophilizing; Perhaps with this lipid film directly with after the water liquid that is dissolved with water-solubility carrier and filmogen mixes, lyophilizing; Get the pro-liposome of flavanolignan's compounds.
7, the preparation method of claim 6 pro-liposome, wherein lower alcohol is selected from methanol and/or ethanol, and rudimentary ether is selected from ether; Lower alcohol and rudimentary ether mix counts 1-15 by weight when using: 1 part; Phosphate buffer is pH4.0-7.8.
8, the preparation method of claim 7 pro-liposome is counted 2-12: 1 part by weight when lower alcohol and rudimentary ether mix use; Phosphate buffer is pH6.8-7.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410014407 CN1264509C (en) | 2004-03-24 | 2004-03-24 | Precursor liposome preparation containing silybum marianum extract and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410014407 CN1264509C (en) | 2004-03-24 | 2004-03-24 | Precursor liposome preparation containing silybum marianum extract and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1561992A CN1561992A (en) | 2005-01-12 |
| CN1264509C true CN1264509C (en) | 2006-07-19 |
Family
ID=34478343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410014407 Expired - Fee Related CN1264509C (en) | 2004-03-24 | 2004-03-24 | Precursor liposome preparation containing silybum marianum extract and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1264509C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199510B (en) * | 2007-12-19 | 2010-06-02 | 江苏大学 | Silybin precursor multiphase lipidosome formulation and preparing method thereof |
| CN101829100B (en) * | 2010-05-25 | 2012-01-11 | 大理学院 | Application of flavanonol lignanoid in preparing antiviral hepatitis B medicine |
| CN102908314A (en) * | 2012-04-29 | 2013-02-06 | 新疆维吾尔自治区包虫病临床研究所 | Silybin proliposomes preparation, and preparation method and application method thereof |
| CN105983013A (en) | 2015-03-23 | 2016-10-05 | 天士力制药集团股份有限公司 | Medicine composition containing silibinin and kudzu vine root extract |
| CN104887630A (en) * | 2015-05-15 | 2015-09-09 | 大连理工大学 | A lipidosome-covered dehydrogenated silibinin phospholipid complex and a preparing method thereof |
| CN110022685A (en) * | 2017-02-14 | 2019-07-16 | 泰国组织工程和干细胞卓越中心 | For improving the water-soluble method of sesamin |
| CN107875121A (en) * | 2017-11-06 | 2018-04-06 | 大连理工大学 | A kind of preparation method of 2,3 dehydro-silibinin phosphatide complexes nano suspension |
| CN110123751A (en) * | 2018-06-14 | 2019-08-16 | 中国药科大学 | A kind of milk thistle class medicament nano cream dust composition and preparation method thereof |
-
2004
- 2004-03-24 CN CN 200410014407 patent/CN1264509C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1561992A (en) | 2005-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150889C (en) | Oral Micro-emulsion composition of silybin | |
| CN1197551C (en) | Dispersion formulations contg. lipase inhibitors | |
| CN1903228A (en) | Prepn. of self-emulsion of glossy ganoderma spore oil, and its prepn. method | |
| US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
| CN101057829A (en) | Supersaturated cationic self-emulsified drug delivery system and its preparation method | |
| CN1264509C (en) | Precursor liposome preparation containing silybum marianum extract and its preparing process | |
| CN1853728A (en) | Method prescription and use for improving medicine or nutrient oral absorption | |
| CN101780037B (en) | Dipyridamole self-emulsifying medicament administration system and preparation method thereof | |
| US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| CN1582159A (en) | Preparing material of flavanol wood lipid with increased solubility | |
| CN101143142A (en) | Silybin supersaturated self-emulsion composition and preparation method thereof | |
| WO2011071194A1 (en) | SOLID DISPERSIONS CONTAINING 20-O-β-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL | |
| CN100477997C (en) | Hydrophobic formulation containing total notoginseng glycosides and phospholipid and preparation method thereof | |
| CN103690482B (en) | Take phosphatide complexes as glycyrrhizic acid self-emulsifiable preparation concentrated solution and the preparation method of intermediate | |
| CN102085238B (en) | Lipid preparation containing radix gentianae totalglycoside-phospholipid complexes and preparation method thereof | |
| CN102008713B (en) | Ciclosporin A proliposome, pharmaceutical composition and preparation method thereof | |
| CN102058537A (en) | Oryzanol solid dispersion composition and preparation thereof | |
| CN1810240A (en) | Prepn process and use of total andrographolide emulsion | |
| CN102319302A (en) | Total paeony glucoside self-microemulsifying soft capsules and preparation method thereof | |
| CN1228051C (en) | Medicinal composition for treating cardiovascular disease | |
| CN1943585A (en) | Breviscapine proliposome powder preparation and its preparing method | |
| CN1457780A (en) | Total alkaloid composition from plant and its pharmaceutical preparation | |
| CN1268342C (en) | Medicine composition | |
| CN1289505C (en) | New compound,its preparation method, medicine preparation using said compound as active component, its action and application | |
| WO2007147371A2 (en) | Pharmaceutical composition for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060719 |